KILN
28.11.2022 10:01:42 CET | Business Wire | Press release
Today, Kiln announced the close of an €17 million financing round to expand their market-leading staking infrastructure product range. Kiln, the leading enterprise-grade staking technology provider, with over $500 million1 of assets staked under management, received funding from Illuminate Financial with participation by a number of leading crypto investing groups including Consensys, GSR, Kraken Ventures, Leadblock Partners, Sparkle Ventures, XBTO and renewed participation from existing investors 3KVC, Blue Yard Capital, SV Angel and Alven among others.
Kiln believes that the staking market is becoming institutionalized and must move beyond running validators to meet the growing customer need to spread risk. This means creating validator-agnostic APIs and services to enable multi-provider staking. This in turn enables digital assets to be staked wherever they are held, for wallets, custodians, and exchanges. As the industry evolves and the need to integrate multiple staking players proves real, Kiln is in an ideal position to play the aggregator role and accelerate it.
Following the Ethereum network’s transition to a Proof of Stake (PoS) consensus (The Merge) in September, which significantly de-risked the protocol roadmap, Kiln predicts the demand for staking ETH to grow exponentially. Currently, only 12.5%2 of ETH supply is staked, compared to 50-80% for other PoS assets. Plus, with an annual percentage yield on ETH in the 6-7%3 range since the Merge, it offers an attractive return-rate for investors.
Staking is the Web3 industry’s native yield: the yield comes from helping secure the blockchain (validating and proposing blocks), and there is no counterparty risk as in lending, or when dealing with a third-party intermediary such as a centralised exchange.
Laszlo Szabo - Co-Founder & CEO at Kiln, said: “I am thrilled to close a robust funding round with such respected investors in the crypto space which will enable us to build out the next generation market standard in staking technology. At Kiln, we believe it is critical to provide enterprise-grade infrastructure to institutional users, that in turn enables our customers to create new opportunities for their users. We thank our existing and new investors for their partnership. The Kiln team couldn't be more excited about this next stage of building out a world-class staking stack.”
The funding, which includes €17 Million in Series A, will be used to add new features to Kiln’s industry leading product range. Kiln already offers the largest product range dedicated to staking on the market with its focus as a technology provider delivering a simple and validator-agnostic staking stack. This includes:
- Kiln Connect, which provides a single SDK to integrate staking, rewards data, and your custodian on all major PoS blockchains
- Kiln On-Chain, which provides smart contracts for seamless ETH staking, any amount of ETH and automated rewards management
- Kiln Dashboard, which provides a 1-click staking dashboard, administration interface, reporting and data exporting
- Kiln Validators, a suite of dedicated or shared validators, with enterprise-grade SLAs, deployed on our multi-cloud Kubernetes infrastructure
Kiln’s customers include industry-leading companies such as Binance US, GSR and Ledger.
Rezso Szabo, Partner at Illuminate Financial, said: "We are witnessing a once in a generation change that will catalyze the institutionalisation of Digital Assets. Sophisticated users and institutions need enterprise grade infrastructure. As a thesis-driven investor backed by traditional financial institutions, we believe the Kiln team has demonstrated they can build key infrastructure that is critical for both digital assets native institutions and will also serve as the future rails for financial services infrastructure. We are excited to partner with such a high-calibre team, who are on a mission to raise the bar in B2B infrastructure for the whole ecosystem."
Ciaran O'Leary, Co-Founder and General Partner of BlueYard Capital, added: “Staking is going to be one of the core fabrics of the entire crypto industry. Kiln’s robust, scalable and safe solutions provide an important fabric for large pools of capital to participate in the core functioning of crypto networks and to generate novel forms of yield. We are excited that Kiln is at the forefront of this new market.”
Benoît Bosc, GSR Global Head of Product, said: “Having used Kiln’s infrastructure to stake our own treasury and in the future to offer to our clients, our company’s missions are perfectly aligned. We are delighted to be able to participate in the next stage of Kiln’s development and to contribute to making staking easier and more accessible to everyone.”
Kiln’s unique team is made up of globally recognized experts in the areas of SaaS, blockchain infrastructure and smart contracts. The company is led by its three co-founders: CEO Laszlo Szabo, a serial entrepreneur who was previously the co-founder of tech recruitment firm Skill Hunter and has been accelerating Web3 adoption since 2017, CPO Ernest Oppetit, a former product manager at Improbable and Qubit; and COO Thomas de Phuoc, who was previously the Country Lead for France at Circle.
Kiln comprises industry leaders including Duncan Hoffman, VP Revenue, who previously led the EMEA region for Chainalysis as General Manager and scaled the business through years of growth that led to an $8.6B valuation. Duncan helped establish Chainalysis as the largest SaaS company in the Web3 industry and market-leading solution for cryptocurrency compliance and investigation use cases to help build trust in blockchains.
1 |
Total as of 11.23.2022 |
2 |
As of 11.23.2022 Source: https://beaconcha.in/ and https://etherscan.io/stat/supply |
3 |
Source Rated.network |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005157/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
